Skip to content

Evommune EVMN Inventory Valuation Adjustments

Inventory Valuation Adjustments at other companies

Evommune
 logo
Evommune EVMN
$10.97K
SEN
Seneca FoodsSENEA
-$182K-102%
Evommune
 logo
Evommune EVMN
$40.96K+1,253%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$150.37M+12.4%
Mayville Engineering logo
Mayville EngineeringMEC
$66.02M+18.3%
APO
Apogee EnterprisesAPOG
$98.06M+6.2%

Other financials

Income statement

See full
Revenue$1.6M+3.5%
Gross profit$961.1K+10.9%
Operating income-$682.8K-2,027%
Net income-$7.0M-5,414%
EPS (diluted)-$0.36-1,700%

Balance sheet

See full
Cash & equivalents$1.1M+401%
Total debt$2.0M
Total equity-$4.5M-3,048%
Total assets$7.2M

Cash flow

See full
Operating cash flow-$424.6K-341%
CapEx$1.0-99.8%
Free cash flow-$2.7M-4,996%

Valuation

See full
Market cap$869.12M+42.8%
Enterprise value$870.05M
P/S130.4×

Profitability

See full
Gross margin53.7%
Operating margin-30.7%
Net margin-90.1%

Returns & leverage

See full
Return on equity275.7%
Debt / equity1.4×
Current ratio1.2×

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:InventoryAdjustments.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's inventory valuation adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evommune 's inventory valuation adjustments?
Evommune (EVMN) reported inventory valuation adjustments of $10.97K in Q1 2026.
What does inventory valuation adjustments mean?
Inventory valuation adjustments reflect changes made to the carrying value of inventory to account for obsolescence, damage, or market price fluctuations. These adjustments ensure that assets are reported at the lower of cost or net realizable value. High levels of adjustment may indicate potential issues with inventory management or the viability of specific research materials.